Aclarion, Inc. (NASDAQ:ACON) Short Interest Update

Aclarion, Inc. (NASDAQ:ACON) saw a significant increase in short interest during the month of December. As of December 15th, there was short interest totaling 42,256 shares, an increase of 142.6% from the November 30th total of 17,416 shares. Based on an average trading volume of 114,351 shares, the short-interest ratio is presently 0.4 days. Approximately 6.3% of the shares of the stock are short sold. Approximately 6.3% of the shares of the stock are short sold. Based on an average trading volume of 114,351 shares, the short-interest ratio is presently 0.4 days.

Aclarion Trading Down 8.3%

Shares of Aclarion stock opened at $5.39 on Friday. Aclarion has a twelve month low of $5.02 and a twelve month high of $3,499.51. The stock has a market cap of $3.61 million, a price-to-earnings ratio of -0.36 and a beta of 1.43. The company has a fifty day moving average price of $6.68 and a 200 day moving average price of $7.24.

Aclarion (NASDAQ:ACON) last issued its earnings results on Wednesday, November 12th. The company reported ($2.93) earnings per share for the quarter, missing the consensus estimate of ($2.64) by ($0.29). The company had revenue of $0.02 million during the quarter, compared to analysts’ expectations of $0.02 million. Aclarion had a negative return on equity of 67.53% and a negative net margin of 10,908.50%. Analysts forecast that Aclarion will post -263.33 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on ACON shares. Wall Street Zen upgraded shares of Aclarion to a “hold” rating in a research report on Saturday. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Aclarion in a research note on Wednesday, October 8th. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, Aclarion presently has an average rating of “Sell”.

Aclarion Company Profile

Aclarion, Inc, a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software. The company was formerly known as Nocimed, Inc and changed its name to Aclarion, Inc in December 2021.